ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1298

Tough Choices: Understanding the Medication Decision-Making Process for Women with Inflammatory Arthritis during Pregnancy and Lactation

Tayseer Haroun1, Amanda M. Eudy2,3,4,5, Malithi Jayasundara2, W. Benjamin Nowell6,7, Jeffrey R. Curtis8, Charlotte Whitney White9, Rachelle Crow-Hercher9, Seth D. Ginsberg10 and Megan E. B. Clowse4,11, 1Department of Medicine/Division of Rheumatology, Duke University Medical Center, Durham, NC, 2Rheumatology, Duke University Medical Center, Durham, NC, 3Duke University, Durham, NC, 4Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, 5Duke University Medical Center, Chapel Hill, NC, 6CreakyJoints/Global Health Living Foundation, Upper Nyack, NY, 7Global Healthy Living Foundation, Upper Nyack, NY, 8Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 9Arthritis Power, Upper Nyack, NY, 10Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, 11Duke University Medical Center, Durham, NC

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Decision analysis, inflammatory arthritis, lactation and pregnancy

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

With new data demonstrating medication compatibility in pregnancy and lactation, it is important to understand how this information can best reach patients. We sought to identify the decision-making process and gaps in knowledge for women of childbearing age regarding their use of rheumatic medication.

Methods:

A cross-sectional study conducted in collaboration with an online arthritis community from March to June 2017. After an e-mail invitation members provided consent by clicking their unique link to the online survey. Participants were women aged 18-50 years with inflammatory arthritis.

Results:

The majority of 250 women who took the survey were white (83%), not Hispanic (82%), college graduates (69%) and had rheumatoid arthritis (80%); average current age was 39.5yrs and age at diagnosis was 26yrs. Sixty eight (27%) women had pregnancies following their arthritis diagnosis and each reported about her most recent pregnancy. Of these, 31% stopped methotrexate (MTX) and 22% stopped TNF-inhibitor (TNFi) prior to pregnancy; 53% took prednisone, DMARDs or biologics during pregnancy. Fifteen percent had inadvertent MTX exposure during their most recent pregnancy. Prednisone was the most common medication in pregnancy and lactation, followed by NSAIDs and TNFi. Most women reported taking medications by physician instruction, but a minority stopped despite physician reassurances.

Of the 37 women who breastfed their last infant (76% of live born infants), 20 (54%) reported taking at least one anti-rheumatic medication (prednisone, DMARD, or biologic) beyond NSAIDs. Prednisone was by far the most common medication used in lactation (17) with only 5 women using a TNFi. Many avoided arthritis medications while breastfeeding: 86% reported either stopping breastfeeding to take medications or avoiding medications to breastfeed. This caused significant distress for some women: “…I decided it would be better for my baby to be able to hold her, than to be breastfed” and “For the first 6 months I flared while breast feeding and… I would have my spouse hold the baby up to my breasts (to) breast feed. I was in bed for 6 months.”

Most women (69%) were very worried about the impact of their medications on a pregnancy. A majority of women talked to their doctor, most commonly a rheumatologist (89%) or obstetrician (OB) (78%), about the risks of medications on pregnancy, with fewer talking to a high-risk OB (39%). Women had the highest level of confidence in the high-risk OB (76% very confident) followed by their rheumatologist (58%) and OB (38%). Among women consulting more than one provider, most (75%) reported receiving a consistent message from their clinicians about medications in pregnancy and lactation. Many women (61%) also searched online for more information.

Conclusion:

As many as half of women reported discontinuing arthritis medications during pregnancy and/or lactation, sometimes suffering with arthritis activity to avoid any perceived risk to the fetus or newborn. Clinical data suggests that many rheumatic medications may be compatible with pregnancy and lactation, but more education is necessary to support women’s decision making about arthritis treatment.


Disclosure: T. Haroun, None; A. M. Eudy, None; M. Jayasundara, None; W. B. Nowell, Global Healthy Living Foundation, 3; J. R. Curtis, Crescendo Biosciences, 2,Crescendo Biosciences, 5; C. Whitney White, None; R. Crow-Hercher, None; S. D. Ginsberg, None; M. E. B. Clowse, Pfizer, Janssen, 5,UCB Pharma, 5.

To cite this abstract in AMA style:

Haroun T, Eudy AM, Jayasundara M, Nowell WB, Curtis JR, Whitney White C, Crow-Hercher R, Ginsberg SD, Clowse MEB. Tough Choices: Understanding the Medication Decision-Making Process for Women with Inflammatory Arthritis during Pregnancy and Lactation [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/tough-choices-understanding-the-medication-decision-making-process-for-women-with-inflammatory-arthritis-during-pregnancy-and-lactation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tough-choices-understanding-the-medication-decision-making-process-for-women-with-inflammatory-arthritis-during-pregnancy-and-lactation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology